<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Delta-8-tetrahydrocannabinol (delta-8-THC), a cannabinoid with lower psychotropic potency than the main Cannabis constituent, delta-9-tetrahydrocannabinol (delta-9-THC), was administered (18 mg/m2 in edible oil, p.o.) to eight children, aged 3-13 years with various <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancers</z:e>, treated with different <z:chebi fb="0" ids="35610">antineoplastic drugs</z:chebi> for up to 8 months </plain></SENT>
<SENT sid="1" pm="."><plain>The total number of treatments with delta-8-THC so far is 480 </plain></SENT>
<SENT sid="2" pm="."><plain>The THC treatment started two hours before each <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> treatment and was continued every 6 hrs for 24 hours </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002013'>Vomiting</z:hpo> was completely prevented </plain></SENT>
<SENT sid="4" pm="."><plain>The side effects observed were negligible </plain></SENT>
</text></document>